Spreading its Wings

IPCA is the country’s largest anti-malarial drug manufacturer. Also, it has a well-established API business as well as a formulations business. Emboldened by the success at home, Ipca is now raring to go out as attractive markets of Africa and US beckon. Sales for this `2,400 crore company (FY12) have compounded at an annual rate of 20 per cent in the last five years while earnings per share compounded at 17 per cent. In the last three years, a change in the business mix has resulted in a faster sales growth of 35 per cent while earnings compounded by an improved 30 per cent. Today, seven of Ipca’s top ten brands are growing faster than their respective industry rates. Strengths and Opportunities Institutional business Ipca is favourably placed when it comes to supplying anti-mala

This article was originally published on September 14, 2012.